308 related articles for article (PubMed ID: 9278332)
1. Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV-1 gp120.
Jankovic D; Caspar P; Zweig M; Garcia-Moll M; Showalter SD; Vogel FR; Sher A
J Immunol; 1997 Sep; 159(5):2409-17. PubMed ID: 9278332
[TBL] [Abstract][Full Text] [Related]
2. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A).
Staats HF; Nichols WG; Palker TJ
J Immunol; 1996 Jul; 157(1):462-72. PubMed ID: 8683152
[TBL] [Abstract][Full Text] [Related]
3. Immunization with an interferon-gamma-gp120 fusion protein induces enhanced immune responses to human immunodeficiency virus gp120.
McCormick AL; Thomas MS; Heath AW
J Infect Dis; 2001 Dec; 184(11):1423-30. PubMed ID: 11709784
[TBL] [Abstract][Full Text] [Related]
4. Induction of gp120-specific protective immune responses by genetic vaccination with linear polyethylenimine-plasmid complex.
Garzón MR; Berraondo P; Crettaz J; Ochoa L; Vera M; Lasarte JJ; Vales A; Van Rooijen N; Ruiz J; Prieto J; Zulueta J; González-Aseguinolaza G
Vaccine; 2005 Feb; 23(11):1384-92. PubMed ID: 15661387
[TBL] [Abstract][Full Text] [Related]
5. Toll-like receptor 4 agonists adsorbed to aluminium hydroxide adjuvant attenuate ovalbumin-specific allergic airway disease: role of MyD88 adaptor molecule and interleukin-12/interferon-gamma axis.
Bortolatto J; Borducchi E; Rodriguez D; Keller AC; Faquim-Mauro E; Bortoluci KR; Mucida D; Gomes E; Christ A; Schnyder-Candrian S; Schnyder B; Ryffel B; Russo M
Clin Exp Allergy; 2008 Oct; 38(10):1668-79. PubMed ID: 18631348
[TBL] [Abstract][Full Text] [Related]
6. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
7. In vivo IL-12 administration induces profound but transient commitment to T helper cell type 1-associated patterns of cytokine and antibody production.
Rempel JD; Wang M; HayGlass KT
J Immunol; 1997 Aug; 159(3):1490-6. PubMed ID: 9233648
[TBL] [Abstract][Full Text] [Related]
8. Modulation of Th1/Th2 immune responses to HIV-1 Tat by new pro-GSH molecules.
Fraternale A; Paoletti MF; Dominici S; Buondelmonte C; Caputo A; Castaldello A; Tripiciano A; Cafaro A; Palamara AT; Sgarbanti R; Garaci E; Ensoli B; Magnani M
Vaccine; 2011 Sep; 29(40):6823-9. PubMed ID: 21816192
[TBL] [Abstract][Full Text] [Related]
9. Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.
Mascarell L; Fayolle C; Bauche C; Ladant D; Leclerc C
J Virol; 2005 Aug; 79(15):9872-84. PubMed ID: 16014948
[TBL] [Abstract][Full Text] [Related]
10. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
Bower JF; Green TD; Ross TM
Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
[TBL] [Abstract][Full Text] [Related]
11. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes.
Chow YH; Chiang BL; Lee YL; Chi WK; Lin WC; Chen YT; Tao MH
J Immunol; 1998 Feb; 160(3):1320-9. PubMed ID: 9570550
[TBL] [Abstract][Full Text] [Related]
12. [Experimental study on immune responses induced in mice by gp120 gene vaccine of Chinese HIV-1 strain].
Wang FX; Sun YT; Sun YN; Xu Z; Wang LX; Bai XF; Huang CX
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 May; 20(3):282-5. PubMed ID: 15193218
[TBL] [Abstract][Full Text] [Related]
13. Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model.
Otero M; Calarota SA; Felber B; Laddy D; Pavlakis G; Boyer JD; Weiner DB
Vaccine; 2004 Apr; 22(13-14):1782-90. PubMed ID: 15068862
[TBL] [Abstract][Full Text] [Related]
14. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 DNA vaccine efficacy is enhanced by coadministration with plasmid encoding IFN-alpha.
Jiang W; Ren L; Jin N
J Virol Methods; 2007 Dec; 146(1-2):266-73. PubMed ID: 17868910
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 Env vaccine comprised of electroporated DNA and protein co-administered with Talabostat.
Cristillo AD; Galmin L; Restrepo S; Hudacik L; Suschak J; Lewis B; Draghia-Akli R; Aziz N; Weiss D; Markham P; Pal R
Biochem Biophys Res Commun; 2008 May; 370(1):22-6. PubMed ID: 18329382
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with gp120-depleted HIV-1 plus immunostimulatory CpG oligodeoxynucleotides in incomplete Freund's adjuvant stimulates cellular and humoral immunity in rhesus macaques.
Silvera P; Savary JR; Livingston V; White J; Manson KH; Wyand MH; Salk PL; Moss RB; Lewis MG
Vaccine; 2004 Dec; 23(6):827-39. PubMed ID: 15542208
[TBL] [Abstract][Full Text] [Related]
18. The control of the antibody isotype response to recombinant human immunodeficiency virus gp120 antigen by adjuvants.
Bomford R; Stapleton M; Winsor S; McKnight A; Andronova T
AIDS Res Hum Retroviruses; 1992 Oct; 8(10):1765-71. PubMed ID: 1457190
[TBL] [Abstract][Full Text] [Related]
19. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection.
Bungener L; Geeraedts F; Ter Veer W; Medema J; Wilschut J; Huckriede A
Vaccine; 2008 May; 26(19):2350-9. PubMed ID: 18400340
[TBL] [Abstract][Full Text] [Related]
20. Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target.
Manocha M; Pal PC; Chitralekha KT; Thomas BE; Tripathi V; Gupta SD; Paranjape R; Kulkarni S; Rao DN
Vaccine; 2005 Dec; 23(48-49):5599-617. PubMed ID: 16099080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
